The Department of Pain Treatment, Gansu Provincial Hospital of TCM, Lanzhou, Gansu 730050, China.
Cui-Ying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, China.
Comput Intell Neurosci. 2022 Jul 16;2022:1493137. doi: 10.1155/2022/1493137. eCollection 2022.
The Traditional Chinese Medicine (TCM) formula Yi-Fei-Jian-Pi-Tang (YFJPT) has been demonstrated effective against Corona Virus Disease 2019 (Covid-19). The aim of this article is to make a thorough inquiry about its active constituent as well as mechanisms against Covid-19 via TCM network pharmacology.
All the ingredients of YFJPT are obtained from the pharmacology database of the TCM system. The genes which are associated with the targets are obtained by utilizing UniProt. The herb-target network is built up by utilizing Cytoscape. The target protein-protein interaction network is built by utilizing the STRING database and Cytoscape. The critical targets of YFJPT are explored by Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG).
The outcomes show that YFJPT might has 33 therapeutic targets on Covid-19, namely, interleukin 2 (IL2), heme oxygenase 1 (HMOX1), interleukin 4 (IL4), interferon gamma (FNG), nuclear factor of kappa light polypeptide gene enhancer in Bcells inhibitor, alpha (NFKBIA), nuclear factor-k-gene binding (NFKB), nitric oxide synthase 3 (NOS3), intercellular adhesion molecule 1 (ICAM1), hypoxia inducible factor 1 subunit alpha (HIF1A), mitogen-activated protein kinase 3 (MAPK3), epidermal growth factor receptor (EGFR), interleukin 10 (IL10), jun proto-oncogene (JUN), C-C motif chemokine ligand 2 (CCL2), C-X-C motif chemokine ligand 8 (CXCL8), tumor protein p53 (TP53), interleukin 1 beta (IL1B), AKT serine/threonine kinase 1 (AKT1), tumor necrosis factor (TNF), interleukin 6 (IL6), erb-b2 receptor tyrosine kinase 2 (ERBB2), RELA proto-oncogene (RELA), NF-B subunit, caspase 8 (CASP8), peroxisome proliferator activated receptor alpha (PPARA), TIMP metallopeptidase inhibitor 1 (TIMP1), transforming growth factor beta 1 (TGFB1), interleukin 1 alpha (IL1A), signal transducer and activator of transcription 1 (STAT1), mitogen-activated protein kinase 8 (MAPK8), myeloperoxidase (MPO), matrix metallopeptidase 3 (MMP3), matrix metallopeptidase 1 (MMP1), and NFE2 like bZIP transcription factor 2 (NFE2L2). The gene enrichment analysis prompts that YFJPT most likely contributes to patients related to Covid-19 by regulating the pathways of cancers.
That will lay a foundation for the clinical rational application and further experimental research of YFJPT.
中药方剂益肺健脾汤(YFJPT)已被证明可有效对抗 2019 年冠状病毒病(Covid-19)。本文旨在通过中医网络药理学深入探究其针对 Covid-19 的活性成分及其作用机制。
YFJPT 的所有成分均从中药系统药理学数据库中获取。利用 UniProt 获取与靶点相关的基因。利用 Cytoscape 构建草药-靶标网络。利用 STRING 数据库和 Cytoscape 构建靶标蛋白-蛋白相互作用网络。利用基因本体论(GO)和京都基因与基因组百科全书(KEGG)探索 YFJPT 的关键靶点。
结果表明,YFJPT 可能针对 33 个新冠病毒靶点,即白细胞介素 2(IL2)、血红素加氧酶 1(HMOX1)、白细胞介素 4(IL4)、干扰素γ(FNG)、κB 细胞中核因子轻肽基因增强子抑制剂,α(NFKBIA)、核因子-κ-基因结合(NFKB)、一氧化氮合酶 3(NOS3)、细胞间黏附分子 1(ICAM1)、缺氧诱导因子 1 亚基α(HIF1A)、丝裂原活化蛋白激酶 3(MAPK3)、表皮生长因子受体(EGFR)、白细胞介素 10(IL10)、原癌基因 jun(JUN)、C-C 基序趋化因子配体 2(CCL2)、C-X-C 基序趋化因子配体 8(CXCL8)、肿瘤蛋白 p53(TP53)、白细胞介素 1β(IL1B)、丝氨酸/苏氨酸蛋白激酶 1(AKT1)、肿瘤坏死因子(TNF)、白细胞介素 6(IL6)、表皮生长因子受体 2(ERBB2)、RELA 原癌基因(RELA)、NF-B 亚基、半胱天冬酶 8(CASP8)、过氧化物酶体增殖物激活受体α(PPARA)、金属蛋白酶抑制剂 1(TIMP1)、转化生长因子β 1(TGFB1)、白细胞介素 1α(IL1A)、信号转导和转录激活因子 1(STAT1)、丝裂原活化蛋白激酶 8(MAPK8)、髓过氧化物酶(MPO)、基质金属蛋白酶 3(MMP3)、基质金属蛋白酶 1(MMP1)和 NFE2 样 bZIP 转录因子 2(NFE2L2)。基因富集分析提示,YFJPT 可能通过调节癌症相关途径,为治疗新冠病毒患者提供帮助。
该研究为 YFJPT 的临床合理应用和进一步的实验研究奠定了基础。